Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study

Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m(2), paclitaxel 155 mg/m(2) (both day 1) and capecitabine 665 mg/m(2) twice daily (days 1–14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achiev...

Descripción completa

Detalles Bibliográficos
Autores principales: Einbeigi, Z., Bergström, D., Hatschek, T., Malmberg, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2008
Materias:
Short Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161650/
https://www.ncbi.nlm.nih.gov/pubmed/21892328
_version_ 1782210714953318400
author Einbeigi, Z.
Bergström, D.
Hatschek, T.
Malmberg, M.
author_facet Einbeigi, Z.
Bergström, D.
Hatschek, T.
Malmberg, M.
author_sort Einbeigi, Z.
collection PubMed
description Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m(2), paclitaxel 155 mg/m(2) (both day 1) and capecitabine 665 mg/m(2) twice daily (days 1–14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.
format Online
Article
Text
id pubmed-3161650
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-31616502011-09-02 Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study Einbeigi, Z. Bergström, D. Hatschek, T. Malmberg, M. Clin Med Oncol Short Review Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m(2), paclitaxel 155 mg/m(2) (both day 1) and capecitabine 665 mg/m(2) twice daily (days 1–14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively. Libertas Academica 2008-09-25 /pmc/articles/PMC3161650/ /pubmed/21892328 Text en © 2008 the author(s), publisher and licensee Libertas Academica Ltd. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license http://creativecommons.org/licenses/by/3.0/).
spellingShingle Short Review
Einbeigi, Z.
Bergström, D.
Hatschek, T.
Malmberg, M.
Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
title Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
title_full Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
title_fullStr Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
title_full_unstemmed Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
title_short Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
title_sort paclitaxel, epirubicin and capecitabine (tex) as first-line treatment for metastatic breast cancer: a pilot phase i/ii feasibility study
topic Short Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161650/
https://www.ncbi.nlm.nih.gov/pubmed/21892328
work_keys_str_mv AT einbeigiz paclitaxelepirubicinandcapecitabinetexasfirstlinetreatmentformetastaticbreastcancerapilotphaseiiifeasibilitystudy
AT bergstromd paclitaxelepirubicinandcapecitabinetexasfirstlinetreatmentformetastaticbreastcancerapilotphaseiiifeasibilitystudy
AT hatschekt paclitaxelepirubicinandcapecitabinetexasfirstlinetreatmentformetastaticbreastcancerapilotphaseiiifeasibilitystudy
AT malmbergm paclitaxelepirubicinandcapecitabinetexasfirstlinetreatmentformetastaticbreastcancerapilotphaseiiifeasibilitystudy

Ejemplares similares